The overall hypothesis of this proposal is that neuronal Ca++ homeostasis plays a major role in opioid analgesia and tolerance by affecting signal transduction systems and K+ channel regulation, which ultimately translates into longterm change in endogenous opioid and neurokinin peptide release.
The aims of this proposal are to: (1) understand how opioid analgesia and tolerance, and (3) elucidate the role of endogenous opioids and neurokinins in opioid analgesia and tolerance. Regarding Ca++- sensitive systems (1), manipulations intended to increase cytosolic Ca++ block acute opioid analgesia, while Ca++ channel antagonists potentiate analgesia. Alternatively, a disruption in Ca++ homeostasis accompanies the development of morphine tolerance, as evidenced by increases in synaptosomal 45 Ca++ uptake and higher free intracellular Ca++ levels in brain and spinal cored synaptosomes. We propose to test the hypothesis that opioid analgesia and tolerance are modulated by the relative activity of calmodulin and the subsequent activation of calmodulin-sensitive adenylate cyclase (and indirectly PKA activity), and/or multifunctional calmodulin-dependent protein kinase II (CaM kinase II). Another potential contributor to analgesia and tolerance is related to the observation that stimulation- induced increases in cytosolic Ca++ activates phospholipase C (PLC) independent of receptor G-protein coupling. We will test the hypothesis that the phosphatidylinositol system plays a role in opioid analgesia, and that opioid tolerance-induced disruptions in Ca++ homeostasis are related to PLC and the subsequent production of IP3 and activation of protein kinase C (PKC). Regarding K+ channel regulation in analgesia and tolerance (2), we have clearly demonstrated that acute morphine analgesia is antagonized by blockers of potassium channels such as glyburide and apamin. Consistent with this are in vitro observations that K+ channel antagonists prevent mu opioid-stimulated k+ efflux and neuronal membrane hyperpolarization. We will test the hypothesis that chronic administration of mu opioids decreases potassium efflux from neurons as compensatory mechanism in the process of the development of tolerance. Regarding neurokinins and endogenous opioids (3), we will evaluate their roles in analgesia and in the development and regulation of opioid tolerance. We hypothesize that besides playing a modulatory role on pain pathways stimulated by excitatory amino acid neurotransmitters, neurokinins mediate endogenous opioid release. We and others have demonstrated that neurokinin agonists produce a naloxone-sensitive analgesia which we propose results from endogenous opioid release. We will test the hypothesis that opioid tolerance involves changes in spinal neurokinin levels or release, and the neurokinins participate in opioid analgesia by releasing endogenous opioids and altering Ca++ homeostasis. These studies are intended to clarify the role of neurokinins and endogenous opioids in tolerance, since their participation in tolerance is frequently obscured.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA001647-22
Application #
2897670
Study Section
Special Emphasis Panel (SRCD (05))
Program Officer
Lin, Geraline
Project Start
1976-12-01
Project End
2001-04-30
Budget Start
1999-05-01
Budget End
2000-04-30
Support Year
22
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Bailey, C P; Oldfield, S; Llorente, J et al. (2009) Involvement of PKC alpha and G-protein-coupled receptor kinase 2 in agonist-selective desensitization of mu-opioid receptors in mature brain neurons. Br J Pharmacol 158:157-64
Bailey, C P; Llorente, J; Gabra, B H et al. (2009) Role of protein kinase C and mu-opioid receptor (MOPr) desensitization in tolerance to morphine in rat locus coeruleus neurons. Eur J Neurosci 29:307-18
Gabra, Bichoy H; Bailey, Chris P; Kelly, Eamonn et al. (2008) Pre-treatment with a PKC or PKA inhibitor prevents the development of morphine tolerance but not physical dependence in mice. Brain Res 1217:70-7
Haller, Victoria L; Bernstein, Marissa A; Welch, Sandra P (2008) Chronic morphine treatment decreases the Cav1.3 subunit of the L-type calcium channel. Eur J Pharmacol 578:101-7
Gabra, Bichoy H; Smith, Forrest L; Navarro, Hernan A et al. (2008) mGluR5 antagonists that block calcium mobilization in vitro also reverse (S)-3,5-DHPG-induced hyperalgesia and morphine antinociceptive tolerance in vivo. Brain Res 1187:58-66
Stoller, Dawn C; Sim-Selley, Laura J; Smith, Forrest L (2007) Role of kappa and delta opioid receptors in mediating morphine-induced antinociception in morphine-tolerant infant rats. Brain Res 1142:28-36
Smith, Forrest L; Lindsay, Raymond J (2007) Enhancement of bupivacaine local anesthesia with the potassium channel blocker ibutilide. Eur J Pain 11:551-6
Bailey, Chris P; Smith, Forrest L; Kelly, Eamonn et al. (2006) How important is protein kinase C in mu-opioid receptor desensitization and morphine tolerance? Trends Pharmacol Sci 27:558-65
Bernstein, M A; Welch, S P (1999) A method for the determination of activated receptor phosphorylation state following in vivo drug treatment. Brain Res Brain Res Protoc 4:420-4
Bernstein, M A; Welch, S P (1998) Inhibition of protein phosphatases alters the expression of morphine tolerance in mice. Eur J Pharmacol 341:173-7

Showing the most recent 10 out of 63 publications